REQUEST A DEMO
Total
USD $0.00
Search more companies

Ntff Polisan OOO (Russia)

Main Activities: Pharmaceutical Preparation Manufacturing | Religious, Grantmaking, Civic, Professional, and Similar Organizations | National Security and International Affairs
Full name: Nauchno-Tehnologicheskaya Farmatsevticheskaya Firma Polisan OOO Profile Updated: March 04, 2022
Buy our report for this company USD 29.95 Most recent financial data: 2022 Available in: English & Russian Download a sample report

Nauchno-Tehnologicheskaya Farmatsevticheskaya Firma Polisan OOO is a pharmaceutical company that focuses on developing antiviral drugs. Their main product, Cycloferon tablets, is a systemic antiviral drug used for the treatment and prevention of various viral infections, including herpes virus. The company's products are targeted towards children and adults from 4 years old, and are used for the treatment and prevention of colds, flu, and other acute respiratory viral infections.

Headquarters
Ulitsa Salova, 72, 2 Lit A
Saint Petersburg; Saint Petersburg; Postal Code: 192102

Contact Details: Purchase the Ntff Polisan OOO report to view the information.

Website: http://cycloferon.ru

Basic Information
Outstanding Shares:
Purchase the Ntff Polisan OOO report to view the information.
Registered Capital:
Purchase the Ntff Polisan OOO report to view the information.
Incorporation Date:
January 10, 1993
Key Executives
Purchase this report to view the information.
General Director
Ownership Details
Purchase this report to view the information.
53.88%
Purchase this report to view the information.
46.12%
Subsidiaries
Polisan ZAO
100%
Polisintez OOO (Belgorod)
100%
Skif OOO
33.7748%
Company Performance
Financial values in the chart are available after Ntff Polisan OOO report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency RUB. Absolute financial data is included in the purchased report.
Net sales revenue
23.63%
Total operating revenue
23.63%
Operating profit (EBIT)
164.08%
Net Profit (Loss) for the Period
274.39%
Total assets
5.13%
Total equity
18.9%
Operating Profit Margin (ROS)
17.26%
Net Profit Margin
16.21%
Return on Equity (ROE)
12.97%
Debt to Equity Ratio
-6.99%
Quick Ratio
1.43%
Cash Ratio
0.06%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?